2 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Hodgkin Disease Recurrent: new trials by email Literature Review of Hodgkin Disease Recurrent trials Research Report on Hodgkin Disease Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Amping up With PemJAK Ruxolitinib, Pembrolizumab - Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma | Phase 2 | Recruiting | Seda S. Tolu | 53 | 2025-12-03 | 2025-12-16 |
| Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy Nivolumab, Autologous CD30.CAR-T, Fludarabine - Classical Hodgkin Lymphoma, Hodgkin Disease Refractory | Phase 1 | Active not recruiting | Tessa Therapeutics | 15 | 2022-07-25 | 2023-04-03 |
| Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) CD30.CAR-T, Fludarabine, Bendamustine - Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent | Phase 2 | Active not recruiting | Tessa Therapeutics | 97 | 2021-02-01 | 2023-04-05 |
Hodgkin Disease (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Lymphoma, T-Cell (1)
Bendamustine Hydrochloride (2) · fludarabine (2) · fludarabine phosphate (2) · Nivolumab (1) · pembrolizumab (1) · ruxolitinib (1)
Tessa Therapeutics (2) · Seda S. Tolu (1)
United States (3)
Helen Heslop, MD (2) · Sairah Ahmed, MD (1) · Seda Tolu, MD (1)